QianJin Pharmaceutical(SH:600479) Chang Jiang Shang Bao·2025-09-23 08:53Core Viewpoint - Qianjin Pharmaceutical (600479.SH) is planning to acquire minority stakes in its subsidiaries to accelerate resource integration amid pressure on its operating performance [1][4]. Group 1: Acquisition Details - The company intends to acquire 28.92% of Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd. and 68% of Hunan Qianjin Xieli Pharmaceutical Co., Ltd. through a combination of issuing shares and cash payments [1][2]. - Post-transaction, Qianjin Pharmaceutical's ownership in Qianjin Xiangjiang Pharmaceutical will increase to 79.92%, while it will fully own Qianjin Xieli Pharmaceutical [2]. - The valuation of Qianjin Xiangjiang Pharmaceutical's equity is estimated at 1.247 billion yuan, reflecting an increase of 583 million yuan (87.77% increase) from its book value, while Qianjin Xieli Pharmaceutical's equity is valued at 387 million yuan, with a 164 million yuan increase (73.28% increase) [2]. Group 2: Financial Performance - Qianjin Pharmaceutical's revenue has fluctuated around 3.6 billion yuan from 2020 to 2024, with net profits showing minimal growth, recorded at 297 million yuan, 302 million yuan, 304 million yuan, 320 million yuan, and a decline to 231 million yuan in 2024 [4]. - In the first half of 2025, the company reported revenues of 1.818 billion yuan and a net profit of 128 million yuan, marking a year-on-year revenue decline of 5.52% but a profit increase of 8.5% [4]. - The two subsidiaries are profitable, with Qianjin Xiangjiang Pharmaceutical projected to generate revenues of 640 million yuan and 704 million yuan in 2023 and 2024, respectively, and net profits of 105 million yuan and 107 million yuan [3]. Qianjin Xieli Pharmaceutical is expected to achieve revenues of 232 million yuan and 248 million yuan, with net profits of approximately 39 million yuan and 24 million yuan for the same periods [3]. Group 3: Strategic Implications - The acquisitions are part of the company's strategic plan to enhance its core competitiveness and profitability by integrating the pharmaceutical business segments [3][5]. - The subsidiaries are considered crucial components of the company's "one main and two auxiliary" strategy in the traditional Chinese medicine industrial sector, aiming to leverage marketing and operational advantages for better synergy [3].